UICC Opens the World Cancer Leaders’ Summit 2025

World Cancer Leaders UICC

“Delivering Innovation with Integrity” - ACT 4 Children Initiative at the 2025 WCLS

ACT 4 Children

Top Growing Medical Universities in USA and Canada: 2025 Edition by BIGR

USA and Canada

Pediatric Cardio-Oncology Consortium to Host Virtual Summit on December 4, 2025

Cardio-Oncology-Consortium

The World’s First Trial of a Vaccine to Prevent Lung Cancer - Cancer Research UK

Cancer Research UK

2025 Selected Abstracts for the European Cancer Summit - European Cancer Organisation

European Cancer Organisation European Cancer Summit

FDA Approves Ziftomenib (Komzifti) for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

ziftomenib

10 Oncology Experts Join OncoDaily Medical Journal’s Editorial Team

OncoDaily Medical Journal

OncoCalendar

« All Events

  • This event has passed.

LATAM Course II: Immunotherapy in Lung Cancer by IASLC

Dec 19, 2024 • 4:00 PM - 5:00 PM
LATAM Course II: Immunotherapy in Lung Cancer by IASLC

LATAM Course II: Immunotherapy in Lung Cancer by IASLC will be held at December 19, 2024.

This exclusive Live Course on the latest updates in lung cancer treatment, specifically focusing on immunotherapy, offers a deep dive into the transformative impact of immunotherapy on lung cancer care in Latin America (LATAM). In Series II of the course, leading thoracic oncology experts from the region will lead discussions on pivotal aspects of immunotherapy in lung cancer treatment.

Key topics will include the integration of biomarkers for immunotherapy, which play a critical role in selecting the right patients and optimizing treatment efficacy. Experts will also explore best management strategies for advanced lung cancer, addressing the evolving landscape of treatment options, and discuss specific challenges faced in clinical practice, such as the management of pneumonitis, a common side effect associated with immunotherapy.

The Link for Registration.

See the Speakers and Series II LATAM Team Below:

LATAM Course II: Immunotherapy in Lung Cancer by IASLC

Details

Organizer